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Chromatin remodeling — a novel strategy to control
excessive alcohol drinking
V Warnault1, E Darcq1, A Levine2, S Barak1,3 and D Ron1
Harmful excessive use of alcohol has a severe impact on society and it remains one of the major causes of morbidity and
mortality in the population. However, mechanisms that underlie excessive alcohol consumption are still poorly understood, and
thus available medications for alcohol use disorders are limited. Here, we report that changing the level of chromatin
condensation by affecting DNA methylation or histone acetylation limits excessive alcohol drinking and seeking behaviors in
rodents. Specifically, we show that decreasing DNA methylation by inhibiting the activity of DNA methyltransferase (DNMT) with
systemic administration of the FDA-approved drug, 5-azacitidine (5-AzaC) prevents excessive alcohol use in mice. Similarly, we
find that increasing histone acetylation via systemic treatment with several histone deacetylase (HDAC) inhibitors reduces mice
binge-like alcohol drinking. We further report that systemic administration of the FDA-approved HDAC inhibitor, SAHA, inhibits
the motivation of rats to seek alcohol. Importantly, the actions of both DNMT and HDAC inhibitors are specific for alcohol, as no
changes in saccharin or sucrose intake were observed. In line with these behavioral findings, we demonstrate that excessive
alcohol drinking increases DNMT1 levels and reduces histone H4 acetylation in the nucleus accumbens (NAc) of rodents.
Together, our findings illustrate that DNA methylation and histone acetylation control the level of excessive alcohol drinking and
seeking behaviors in preclinical rodent models. Our study therefore highlights the possibility that DNMT and HDAC inhibitors
can be used to treat harmful alcohol abuse.
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Introduction
Alcohol use disorders are the second most detrimental
neuropsychiatric disorder.1 Four percent of deaths worldwide
are associated with alcohol abuse,2 and chronic harmful
alcohol use is one of the four most common risk factors for
multiple diseases such as cardiovascular diseases and
diabetes, and is the third largest risk factor for reduced
productivity.2 Finally, alcohol has been rated as the most
harmful drug to oneself and others.3 However, the central
molecular mechanisms underlying harmful excessive alcohol
intake are not well understood and thus treatment options
remain limited with modest efficacy.
The alteration in gene expression is one of the central
features underlying neuroadaptations that result from chronic
drug and alcohol use.4,5 One means of controlling gene
expression is the remodeling of chromatin structure.6 Speci-
fically, chromatin condensation and decondensation block or
allow, respectively, the accessibility of gene promoters to the
transcriptional machinery.6 Chromatin is formed by a DNA
molecule wrapped around an octomer of histones (H2A, H2B,
H3 and H4).6 Histone acetylation promotes chromatin relaxa-
tion that allows gene expression, whereas histone deacetyla-
tion, catalyzed by histone deacetylases (HDACs), leads to
chromatin condensation and to repression of transcription.6
Among the HDAC superfamily, classes I and IIa are the most
abundant in the brain.7 DNA methylation occurs on specific
cytosine-guanine dinucleotide domains (CpG islands) within
gene promoters and is catalyzed by DNA methyltransferases
(DNMT).8 Methylated-CpG islands are binding sites forMethyl
CpG binding protein 2 (MeCP2), which forms a protein
complex with HDAC that represses gene transcription by
promoting chromatin condensation at the promoter.8,9
Animal and human studies suggest that alterations in DNA
methylation and histone acetylation contribute tomechanisms
that underlie psychiatric disorders including drug addic-
tion.10,11 Specifically for alcohol, decreases in Neuropeptide
Y expression in the central and medial amygdala induced by
alcohol withdrawal in rats are due to a decrease in histone
acetylation, which is linked to HDAC hyperactivation,12 and
human studies have revealed that alcoholics display altera-
tions in methylated DNA profile and DNMT levels.13–17 These
data suggest that modifications in chromatin remodeling by
alcohol may be a focal point in neuroadaptations resulting in
continuous excessive alcohol seeking and intake. If so,
modifiers of chromatin structure can be used for the treatment
of alcohol use disorders.
Materials and methods
Information on reagents, animals, preparation of solutions,
systemic administration of inhibitors, blood alcohol concen-
tration measurements, mouse experiments (intermittent
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access to 20% alcohol or 0.03% saccharin 2-bottle choice,
intermittent limited access to 20% alcohol or 0.03% saccharin
in drinking in the dark (DID)), rat experiments (self-adminis-
tration of 20% alcohol and 1.5% sucrose), sample prepara-
tions, western blot analysis and statistical analyses are
available in Supplementary information.
Results
Systemic administration of 5-azacitidine reduces 20%
alcohol drinking, but not saccharin intake, in mice.
Inhibition of DNMT activity reduces the level of DNA
methylation, which, in turn, increases gene expression by
promoting chromatin decondensation at the promoter.8,9,18
We therefore determined whether reducing DNA methylation
via inhibiting DNMT activity18 reduces alcohol intake. To do
so, we tested the effect of the DNMT inhibitor, 5-azacitidine
(5-AzaC), an FDA-approved drug for the treatment of certain
forms of cancer, on excessive alcohol drinking in mice by
using the intermittent access to 20% alcohol 2-bottle choice
procedure. After 8 weeks of alcohol exposure, mice reached
a high level of alcohol intake (B7g/kg during the first 4 h
and B21 g/kg during the entire session; Supplementary
Figure S1a) and preference ratio (B0.75; Supplementary
Figure S1b). Furthermore, with this procedure, mice experi-
ence repeated cycles of alcohol binge drinking and with-
drawal similar to those of human abusers of alcohol.19
Previous studies showed that 5-AzaC is most effective when
administered repeatedly in animal models for depression,20
therefore we used here a similar regime. Specifically, mice
were treated systemically (intraperitoneal, i.p.) with 5-AzaC,
24, 18 and 2h before the beginning of the test session
(Supplementary Figure S2a). A within-subject design was
used to test the effect of the drug, with mice receiving either
5-AzaC or vehicle once a week according to a Latin square
experimental design. We found that 5-AzaC significantly
decreased binge consumption of alcohol as measured during
the first 4 h of alcohol access (one-way repeated measures
analysis of variance (RM-ANOVA), F(2,18)¼ 20.4, Po0.001;
post hoc, Pso0.001; Figure 1a). Our results also show that
5-AzaC reduced alcohol consumption (one-way RM-ANOVA,
F(2,18)¼ 7.4, Po0.01; Figure 1b) and preference (one-way
RM-ANOVA, F(2,18)¼ 3.9, Po0.05; Figure 1c) during a 24-h
alcohol-drinking session but not during the subsequent
drinking session (Supplementary Figure S3). Post hoc
analysis revealed that 5-AzaC at 0.5 and 1.0mg/kg
significantly reduced alcohol drinking (Pso0.05; Figure 1b),











































































































































Figure 1 Systemic administration of 5-azacitidine (5-AzaC) reduces excessive alcohol intake, but not saccharin intake, in mice. (a–d) Mice undergoing intermittent access
to 20% alcohol 2-bottle choice for 24 h were systemically administered (intraperitoneal, i.p.) with 5-AzaC (0.50–1.0 mg/kg) or its vehicle (Veh) 24, 18, and 2 h before the
initiation of the test alcohol-drinking session. (a) Amount of alcohol (g/kg) consumed during the first 4 h of 20% alcohol access. (b) Amount of alcohol (g/kg) consumed
during the last 20 h of 20% alcohol access. (c) Preference for alcohol is calculated as the ratio of the volume of alcohol solution intake/volume of total fluid intake during the last
20 h of 20% alcohol access. (d) Water intake during the last 20 h of 20% alcohol access. Results are expressed as mean±s.e.m., *Po0.05, **Po0.01 and ***Po0.001
compared with vehicle. (a–d) n¼ 10. (e–g) Mice with intermittent access to 0.03% saccharin for 24 h in a 2-bottle choice procedure were systemically administered (i.p.) with
1 mg/kg 5-AzaC as described above. Amount of saccharin solution (ml kg 1) consumed during the first 4 h (e) and the last 20 h of access (f). (g) Preference ratio for saccharin
solution during the last 20 h of access. Results are expressed as mean±s.e.m. (e–g) n¼ 10.
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for the alcohol solution (Po0.05; Figure 1c). 5-AzaC
treatment did not modify water intake (Figure 1d), nor
did it change the kinetics of blood alcohol clearance
(Supplementary Figure S4).
Next, to evaluate whether the effects of 5-AzaC were
specific to alcohol or were due to a generalized inhibition of
reward, we tested the effect of the DNMT inhibitor on
saccharin intake. Mice undergoing intermittent access to
0.03% saccharin (2-bottle choice; Supplementary Figures
S5a and b) were systemically treated with 1mg/kg 5-AzaC
24, 18 and 2 h before the beginning of the test session.
A within-subject design, as detailed above for alcohol, was
used to test the effect of the drug on saccharin intake
(Supplementary Figure S2a). In contrast, we found that
5-AzaC does not modify the level of saccharin consumption
(paired t-test: first 4 h t(9)¼ 0.15, P¼ 0.88; Figure 1e, and the
last 20 h t(9)¼  0.10, P¼ 0.92; Figure 1f) or preference
(paired t-test, t(9)¼  0.09, P¼ 0.93; Figure 1g). This result
indicates that DNMT inhibition reduces both alcohol intake
and preference, but that effect is not generalized to other
rewarding substances. Together, these results suggest that
promoting chromatin decondensation via inhibiting DNMT
activity reduces alcohol drinking.
Systemic administration of HDAC inhibitors reduces
binge-like alcohol drinking, but not saccharin, intake in
mice. Another way to increase chromatin relaxation and
induce gene expression is by enhancing histone acetylation
via the inhibition of HDAC activity.21–23 We therefore
evaluated whether the administration of HDAC inhibitors
modifies the level of binge-like 20% alcohol drinking. We
used a second well-established preclinical drinking model in
mice, in which mice have intermittent access to a single
bottle of 20% alcohol for 4 h beginning 2 h into the
dark cycle.24,25 This procedure also promotes high levels
of consumption (B7g/kg per 4 h), and generates pharma-
cologically relevant blood alcohol concentrations of
B100mg%,24 which corresponds to the definition of binge
drinking in humans.26 In this paradigm, mice experience
periods of alcohol binge drinking and withdrawal similar to
what human alcohol abusers encounter.19 Three different




















































































































Figure 2 Systemic administration of HDAC inhibitors reduces binge-like alcohol drinking, but not saccharin consumption, in mice. Mice undergoing an intermittent access
to 20% alcohol in drinking in the dark (DID) limited access procedure were systemically administered (intraperitoneal, i.p.) with vehicle (Veh), TSA (a), SAHA (b) or MS275
(c) 2 h before the beginning of the alcohol-drinking session. (a–c) Amount of alcohol (g/kg) consumed during the 4 h of 20% alcohol access after TSA (0.02–0.4 mg/kg),
SAHA (25–100 mg/kg) or MS275 (1–20 mg/kg) treatment. Results are expressed as mean±s.e.m. alcohol consumed during a 4-h session in g/kg, *Po0.05, **Po0.01,
***Po0.001 compared with vehicle. (a) n¼ 9, (b) n¼ 15, (c) n¼ 10. (d) Mice undergoing the 20% alcohol DID procedure were systemically administered with vehicle (Veh)
or SAHA (50 mg/kg) daily for 7 days. Results are expressed as mean±s.e.m., **Po0.01, ***Po0.001 compared with vehicle. n¼ 10. (e) Mice with access to a saccharin
solution (0.03%, w/v) in the DID procedure were systemically administered (i.p.) with vehicle (Veh), TSA (0.4 mg/kg), SAHA (100 mg/kg) or MS275 (20 mg/kg) 2 h before the
beginning of the saccharin-drinking session. Results are presented as mean±s.e.m. and expressed as percentage of the saccharin solution consumed by the vehicle group
during a 4-h session. Veh n¼ 17, TSA n¼ 8, SAHA n¼ 9, MS275 n¼ 8.
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mice (for baseline levels of alcohol intake, see
Supplementary Table S1). A within-subject design was used,
with mice receiving either vehicle or an HDAC inhibitor once
a week according to a Latin square experimental design.
HDAC inhibitors were administered 2 h before the beginning
of alcohol access session (Supplementary Figure S2b). As
shown in Figures 2a and b, systemic administration of pan
HDAC class I and II inhibitors, TSA and SAHA, produced a
significant dose-dependent decrease in 20% alcohol drinking
in mice (one-way RM-ANOVA, TSA (F(4,31)¼ 8.2, Po0.001),
SAHA (F(3,42)¼ 23.5, Po0.001)). Post hoc analysis revealed
that all doses of TSA tested, except 0.02mg/kg, reduced
binge-like alcohol drinking (Pso0.05; Figure 2a) and SAHA
significantly inhibited alcohol binging at 50 and 100mg/kg
(Pso0.001), but not at 25mg/kg (Figure 2b).
Alcohol has been reported to activate HDAC2, a class I
HDAC.27 We therefore sought to determine whether the
selective inhibition of class I HDAC using MS275 prevents
binge-like alcohol drinking, and found that systemic adminis-
tration of the drug dose dependently inhibited the excessive
levels of alcohol consumed by mice (one-way RM-ANOVA,
F(5,43)¼ 6.84, Po0.001) at doses higher than 2.5mg/kg
(Post hoc, Pso0.05; Figure 2c).
As a single acute administration of all three HDAC inhibitors
did not have a long-lasting effect on alcohol intake
(Supplementary Figures S6a–c), we next tested the effect of
a subchronic systemic administration of one of the inhibitors,
SAHA, on binge-like alcohol drinking. To do so, mice received
a daily i.p. administration of SAHA (50mg/kg) or vehicle at
1000h (that is, 2 h before the beginning of the alcohol-drinking
session) every day for 7 consecutive days using a between-
subject design (Supplementary Figure S2c). Daily SAHA
administration began on a day of scheduled alcohol access,
and alcohol consumption was recorded over the next
four sessions of alcohol access (Supplementary Figure
S2c). We found that daily systemic administration of SAHA
significantly reduced binge-like alcohol drinking over the
four sessions of access to alcohol (two-way RM-ANOVA, a
main effect of treatment (F(1,18)¼ 35.46, Po0.001), with no
effect of session (F(3,54)¼ 0.69, P¼ 0.56), and no interaction
(F(3,54)¼ 0.69, P¼ 0.56); Figure 2d). Interestingly, the effect
of SAHA persisted through the first session of alcohol access
following the end of treatment (two-way RM-ANOVA, treat-
ment (F(1,18)¼ 3.54, P¼ 0.076), session (F(3,52)¼ 2.66,
P¼ 0.058), interaction (F(3,52)¼ 5.73, Po0.01); Figure 2d).
Next, to evaluate whether the effects of HDAC inhibitors
were specific to alcohol or were due to a generalized inhibition
of reward, TSA, SAHA and MS275 (0.4, 100 and 20mg/kg,
respectively) were administered systemically (i.p.) and the
intake of 0.03% saccharin was measured. Mice experienced
2 weeks of abstinence from alcohol followed by 2 weeks of
saccharin intake before the test (Supplementary Figure S2b,
for baseline level of saccharin intake see Supplementary
Table S1). A within-subject design was used to test the drugs,
with mice receiving either the vehicle or an HDAC inhibitor
once a week according to a Latin square experimental design.
We found that the HDAC inhibitors did not alter the level of
saccharin intake (one-way ANOVA, F(3,38)¼ 0.05, P¼ 0.98;
Figure 2e). This result demonstrates that the reduction in
alcohol intake induced by HDAC inhibition is selective for
alcohol and not a consequence of a decrease in the total
volume of fluid intake or a generalized attenuation of reward.
Together, these results suggest that promoting chromatin
relaxation by inhibiting the activity of HDACs, and specifically
HDAC2, inhibits binge-like alcohol drinking.
Systemic administration of SAHA selectively reduces
alcohol operant self-administration and seeking in rats.
To test whether HDAC inhibition reduces the motivation to
consume and/or seek alcohol, we evaluated the effect of
systemic SAHA administration on alcohol operant self-
administration in rats. Rats with history of intermittent access
to 20% alcohol were trained to press a lever for a 20%
alcohol aliquot (0.1ml) under an FR3 reinforcement schedule
(that is, three presses on the active lever resulted in one
reward delivery) during 30-min sessions. Once rats reached
a stable baseline responding (Supplementary Table S2), rats
received a systemic administration (i.p.) of 50mg/kg
SAHA or its vehicle (Supplementary Figure S2d). A within-
subject design was used to test the effect of SAHA, with rats
receiving either vehicle or the HDAC inhibitor once a week
according to a Latin square experimental design. We found
that SAHA treatment reduced the number of presses for the
active-lever without affecting inactive-lever presses (two-way
RM-ANOVA, main effects of treatment (F(1,8)¼ 10.1,
Po0.05) and lever (F(1,8)¼ 71.9, Po0.001), interaction
(F(1,8)¼ 7.8, Po0.05); Figure 3a). A significant reduction in
the level of alcohol intake was also observed (paired t-test,
t(8)¼ 3.4, Po0.05; Figure 3b). Rats returned to baseline lever
presses the next day (Supplementary Figure S7), further
confirming that a single administration of SAHA does not




















































Figure 3 Systemic administration of SAHA selectively reduces operant self-
administration of alcohol in rats. (a, b) Rats with a history of intermittent access to
20% alcohol were trained to self-administer 20% alcohol under an FR3 schedule
during 30-min sessions. Two hours before the beginning of the test session, rats
received an intraperitoneal (i.p.) administration of vehicle (Veh) or 50 mg/kg
SAHA. (a) Number of lever presses during the 30-min test session. (b) Amount of
alcohol (g/kg) consumed during the 30-min test session. Results are expressed as
mean±s.e.m., *Po0.05 and ***Po0.001 compared with vehicle. n¼ 9.
(c) Rats were trained to self-administer 1.5% sucrose under an FR3 schedule
during 30-min sessions. Two hours before the beginning of session, rats received an
i.p. administration of vehicle (Veh) or 50 mg/kg SAHA. Data are represented as
number of lever presses during the 30-min test session. Results are expressed as
mean±s.e.m. n¼ 6 per group.
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inhibition suppresses alcohol self-administration in rats.
Furthermore, analysis of the cumulative alcohol deliveries
during the 30-min test session shows that rats treated with
SAHA had a lower overall rate of alcohol drinking (two-way
RM-ANOVA, main effects of the treatment (F(1,8)¼ 10.2,
Po0.05) and time (F(14,112)¼ 64.8, Po0.001), interaction
(F(14,112)¼ 4.6, Po0.001); Supplementary Figure S8a). Post
hoc analysis confirmed that rats treated with SAHA displayed
a lower number of alcohol deliveries for all intervals later than
6–8min compared with vehicle-treated rats (Pso0.05).
Moreover, the latency for the last 20% alcohol delivery
occurred earlier in SAHA-treated rats as compared with
controls (paired t-test, t(8)¼ 3.0, Po0.05; Supplementary
Figure S8b). In contrast, SAHA treatment did not affect the
latency to the first alcohol delivery (Supplementary Figure
S8c). The distribution of inter-response intervals was similar
between both SAHA and vehicle groups, indicating that the
interval of time between two consecutive active-lever
presses is not affected by the treatment (two-way RM-
ANOVA, F(1,8)¼ 1.9, P¼ 0.2; Supplementary Figure S8d).
Together, these results show that SAHA induces an early
termination of the drinking episode without altering the
mobility of the animal.
We then asked whether the reduction in alcohol consump-
tion seen with SAHA treatment was a result of a general
reduction in drive for appetitive stimuli or change in the ability
of the animal to move and perform various tasks. These
possibilities have important potential implications for possible
clinical trials. To answer this question, a between-subject
design was used to test the effect of SAHA (50mg/kg) on
operant responding for 1.5% sucrose (Supplementary Table
S3; Supplementary Figure S2d). Before the test session, the
level of active-lever presses was 87.7±23.1 and 82.5±16.9
in the vehicle and SAHA groups (unpaired t-test, t(10)¼ 0.18,
P¼ 0.86) respectively. We found that SAHA treatment did not
alter the level of sucrose deliveries (two-way RM-ANOVA, no
main effect of treatment (F(1,10)¼ 0.8 10 4, P¼ 0.98), main
effect of lever (F(1,10)¼ 40.9, Po0.001), no interaction
(F(1,10)¼ 0.02, P¼ 0.89); Figure 3c). This result demonstrates
that the effect of SAHA on operant self-administration is
selective for alcohol and is not the consequence of impair-
ments in locomotion.
Next, to evaluate whether SAHA affects the motivation to
seek alcohol, we tested its action on instrumental perfor-
mance during an extinction session (that is, when active-lever
presses did not result in alcohol delivery). In this condition,
persistent pressing on the lever previously associated
with reward delivery (for example, alcohol) during the test
session is a measurement of reward seeking.24,28 The more
rats press on the reward-associated lever during the entire
session of extinction, the more they display a high level
of reward seeking. Alcohol-seeking behavior was tested
after 2 weeks of self-administration without any manipulation
(Supplementary Figure S2d). Before the first session of
extinction, the levels of active-lever presses were 64.7±10
and 66.5±11.9 in the vehicle and SAHA groups, respectively
(unpaired t-test, t(10)¼  0.11, P¼ 0.91). A between-subject
designwas used to test the effect of SAHA on alcohol seeking.
We found that i.p. administration of SAHA (50mg/kg)
decreased alcohol seeking in rats as indicated by a reduction
in the number of alcohol-associated lever (that is, the
previously active lever) presses, without affecting the presses
on the non-alcohol associated lever (that is, the previously
inactive lever) (two-way RM-ANOVA, main effects of
treatment (F(1,10)¼ 6.8, Po0.05) and lever (F(1,10)¼ 40.9,
Po0.001), interaction (F(1,10)¼ 8.1, Po0.05); Figure 4a).
Furthermore, the analysis of cumulative lever presses
revealed that SAHA reduced the overall rate of alcohol-
associated lever presses during the 30-min test session (two-
way RM-ANOVA, main effects of treatment (F(1,10)¼ 5.0,
Po0.05) and time (F(14,140)¼ 24.3, Po0.001), interaction
(F(14,140)¼ 5.6, Po0.001); Figure 4b). Post hoc analysis
confirmed that SAHA induced a decrease in the number of
alcohol-associated lever presses for all intervals later than
10–12min (Pso0.05; Figure 4b). SAHA-treated rats stopped
pressing the alcohol-associated lever earlier (743.2±231 s)
compared with vehicle-treated rats (1306.6±105 s, unpaired
t-test, t(10)¼ 2.22, P¼ 0.05). In contrast, SAHA treatment did




















































































Figure 4 Systemic administration of SAHA reduces alcohol seeking, but not
sucrose seeking, in rats. (a–c) Rats underwent the same alcohol administration
paradigm as described in the legend of Figure 3. Two hours before the beginning of
the single extinction session, rats received an intraperitoneal (i.p.) administration of
vehicle (Veh) or 50 mg/kg SAHA. (a) Number of lever presses during a 30-min
extinction session. (b) Cumulative mean presses in bins of 2 min, indicative of the
rate of alcohol-associated lever presses during a 30-min extinction session. (c)
Latency to the third alcohol-associated lever presses. Results are expressed as
mean±s.e.m., **Po0.01 compared with vehicle. (a–c) n¼ 6 per group. (d) Rats
trained to self-administer 1.5% sucrose under an FR3 schedule (30-min) received
an i.p. administration of vehicle (Veh) or 50 mg/kg SAHA 2 h before the beginning of
the first extinction session. Data represent the number of lever presses during the
30-min extinction session. Results are expressed as mean±s.e.m. Veh n¼ 6 and
SAHA n¼ 7.
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press (that is, when the first alcohol delivery should occur)
(Figure 4c). Together, these results suggest that SAHA-
mediated HDAC inhibition represses alcohol seeking in rats
both in the presence and in the absence of alcohol.
Finally, we determined whether SAHA affects the
motivation to seek sucrose during a single extinction session.
Sucrose-seeking behavior was tested in the same groups
of rats after 2 weeks of regular self-administration without
any drug manipulation (Supplementary Figure S2d). The
basal levels of active-lever presses before the first session
of extinction were 83.16±16.5 and 85.7±21.0 in the
vehicle and SAHA groups, respectively (unpaired t-test,
t(10)¼  0.09, P¼ 0.93). SAHA-treated rats showed the
same level of sucrose seeking compared with vehicle-treated
rats (two-way RM-ANOVA, no main effect of treatment
(F(1,11)¼ 1.2 10 4, P¼ 0.97), main effect of lever
(F(1,11)¼ 31.4, Po0.001), no interaction (F(1,11)¼ 0.02,
P¼ 0.88); Figure 4d). This result confirms that SAHA is
selective for alcohol and demonstrates that its effect is not the
consequence of a general reduction in motivation to obtain a
reward or because of impairments in memory.
Excessive alcohol intake increases DNMT levels and
reduces Histone H4 acetylation in the nucleus accum-
bens. As described above, we found that inhibition of
DNMT1 or HDAC activity reduced alcohol intake in rodents.
We hypothesized that exposure of mice/rats to alcohol
results in an increase in the level or activity of DNMT1 or
HDACs, which is attenuated upon administration of the
inhibitors. We therefore first tested whether excessive
alcohol drinking alters DNMT1 levels in the nucleus
accumbens (NAc), a key component of the brain’s reward
circuitry that has an important role in the expression of
behavioral phenotypes associated with alcohol exposure.29
As shown in Figure 5a, we found that the levels of DNMT1
were significantly higher in the NAc of mice consuming
alcohol compared with mice that consumed water only
(water; unpaired t-test, t(4)¼  3.74, Po0.05).
The substrates of HDACs are histones, the major compo-
nent of the chromatin structure.6 As the level of histone
H4 acetylation is particularly associated with the effects of
drugs of abuse,30,31 we sought to determine whether
binge-like drinking alters histone H4 acetylation in the NAc.
As shown in Figure 5b, binge-like alcohol drinking reduced
the level of acetylated histone H4 in the NAc of mice (unpaired
t-test, t(11)¼ 4.17, Po0.01) without affecting the total level
of histone H4 (unpaired t-test, t(10)¼ 0.41, P¼ 0.69).
Finally, we examined whether the reduction in the level of
histone acetylation by alcohol is observed across species.
To do so, we measured the level of acetylated histone in
the NAc of rats that self-administered 20% alcohol and in
age-matched alcohol-naı¨ve rats. As shown in Figure 5c,
rats undergoing operant self-administration procedure exhibit
a reduced level of acetylated histone H4 in the NAc
(unpaired t-test, t(6)¼ 4.16, Po0.01) without affecting the
total level of histone H4 (unpaired t-test, t(7)¼  0.04,
P¼ 0.97). Together, these results show that excessive intake
of alcohol increases the level of DNMT1 and produces
hypoacetylation of histone H4 in the NAc, suggesting that
HDAC activity is increased.
Discussion
Harmful excessive alcohol use has devastating conse-
quences that can lead to physical dependence and recurring
relapse episodes.1–3,29 Unfortunately, pharmacotherapies
available to treat or prevent alcohol abuse disorders are very




















































































Figure 5 Excessive alcohol intake increases DNA methyltransferase 1
(DNMT1) levels and reduces the level of Histone H4 acetylation. (a) Mice nucleus
accumbens (NAc) slices were collected 4 h after the beginning of 20% alcohol
access. DNMT1 level was determined by western blot analysis. Age-matched
alcohol-naı¨ve mice consuming only water were used as control. GAPDH was used
as a loading control. Results are expressed as mean of image density of DNMT1/
GAPDH±s.e.m., *Po0.05 compared with water. n¼ 3. (b) Mice NAc slices were
collected after a 4-h session of 20% alcohol access in the drinking in the dark (DID)
procedure. Age-matched alcohol-naı¨ve mice consuming only water were used as
control. Total histone H4 (H4) and acetylated H4 (AcH4, pan-acetylated-lysine
antibody) levels were determined by western blot analysis. GAPDH was used as a
loading control. Results are expressed as mean of image density of H4 or AcH4/
GAPDH±s.e.m., **Po0.01 compared with water. n¼ 6–7. (c) Rat NAc slices
were collected at the end of a 20% alcohol operant self-administration session of
30 min. The controls, age-matched alcohol-naı¨ve rats, were concomitantly confined
to the behavioral chamber for 30 min with access to the levers, but lever presses
had no associated consequences. Results are expressed as mean H4 or AcH4/
GAPDH±s.e.m., **Po0.01 compared with water. n¼ 4–5.
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agents that induce chromatin decondensation have the
potential to be developed as medications to treat harmful
excessive alcohol consumption, as well as alcohol seeking.
Specifically, using preclinical murine models, we demonstrate
that reducing DNA methylation via the systemic administra-
tion of a DNMT inhibitor reduces acute episodes of binge
drinking, as well as excessive alcohol intake during a 24-h
session in mice without affecting saccharine intake or alcohol
metabolism. Similarly, we found that HDAC inhibition, which
also produces relaxation of the chromatin structure, leads to
an inhibition of binge-like alcohol, but not saccharin drinking.
Both types of inhibitors reduced excessive consumption in
mice experiencing successive cycles of alcohol drinking and
withdrawal in a similar manner to human alcohol abusers,19
making the results particularly relevant in the context of
studying alcohol abuse and harmful alcohol use. Importantly,
we demonstrate that systemic administration of the FDA-
approved drug, SAHA, produces a specific suppression in the
motivation of rats to self-administer and seek excessive
amounts of alcohol but not sucrose. We also show that SAHA
produces a specific inhibition of alcohol-seeking behavior, a
finding that is of particular interest because subjects with
alcohol abuse disorders report high levels of craving for
alcohol (seeking), which induces persistence in alcohol-
drinking behavior that makes it difficult to initiate or maintain
abstinence.29
Our findings are in agreement with previous reports
indicating that HDAC inhibition suppresses behaviors related
to drugs of abuse. For instance, systemic administration of
HDAC inhibitors decreases cocaine taking- and cocaine-
seeking behavior,33–35 as well as prevent nicotine-induced
conditioned place preference.36 In contrast with our findings,
Wolstenholme et al.37 reported that subchronic treatment with
TSA increased alcohol intake 3 weeks after the end of the
treatment. This discrepancy may stem from differences in the
regimen of TSA administration (2mg/kg, once a day for
5 days compared with an acute administration used herein),
as well as differences in drinking procedure (2-bottle choice
continuous access to 10% alcohol leading to an intake of
moderate (B4 g/kg) level of alcohol, compared with inter-
mittent access to 20% alcohol leading to an intake of
B7g/kg herein). Importantly, we were able to replicate our
results with three different HDAC inhibitors, in two different
behavioral procedures and in two different species, providing
strong preclinical evidence that chromatin relaxation reduces
excessive binge-like alcohol-drinking behaviors.
Importantly, from a therapeutic perspective, we show that
alteration of chromatin remodeling does not affect saccharin
and sucrose intake indicating that the inhibitors do not
produce a general effect on motivation to consume a
rewarding solution.38 The selectivity of SAHA to reduce
alcohol but not sucrose intake in rats is in contrast with the
effects of naltrexone and acamprosate, both FDA-approved
drugs currently used to treat alcohol craving. Naltrexone and
acamprosate repress water and sucrose intake,39–42 and
compliance issues associated with the two drugs are likely to
be due to a general reduction in motivation.43,44
Finally, our study is of particular interest from a clinical
perspective, as we tested the actions of two FDA-approved
drugs, SAHA (Zolinzas, Merck & Co., Whitehouse Station,
NJ, USA) and 5-AzaC (Vidazas, Celgene Corporation,
Summit, NJ, USA), which have been used as therapeutic
agents for the treatment of several types of cancers45–48 (see
also http://www.ClinicalTrials.gov). In addition, phase II
clinical trials using MS275 (Entinostat) are in progress for
Hodgkin’s lymphoma and, breast and lung cancer (http://
www.ClinicalTrials.gov), and interestingly, several reports
indicate that 5-AzaC, SAHA, and MS275 show a potential
antidepressant use.20,23,49
Methylated DNA at gene promoters represses transcription
by condensing the chromatin,8,9 and reducing DNA methyla-
tion by inhibiting DNMT activity has been shown to increase
gene expression.18,49,50 Conversely, histone acetylation
leads to chromatin decondensation, which, in turn, enhances
gene expression making promoters accessible for transcrip-
tional machinery.6 Inhibition of HDAC activity spares the
acetylated form of the histones, thus contributing to enhanced
gene expression.21–23 Our results suggest that the level of
gene expression controlled by chromatin structure accounts
for the amount of alcohol intake and that a reduction in
excessive alcohol intake requires an increase in specific
gene products. It is also possible that DNMT and HDAC
inhibitors produce an increase in genes whose expression is
reduced by alcohol intake. In line with this possibility, we
found that excessive alcohol drinking leads to increased
levels of DNMT1 and hypoacetylation of histone H4 in the
NAc of rodents. Theses alterations may lead to the
condensation of chromatin and a repression of gene expres-
sion. Thus, it is plausible that DNMT and HDAC inhibitors
reduce alcohol drinking and seeking by adjusting the
activity of DNMT1 and the level of histone H4 acetylation in
the NAc, and possibly other brain regions. This possibility
is in line with recent publications analyzing the effect of
alcohol intake on the transcriptome in different brain regions
that suggest that while alcohol intake increases the expres-
sion of some genes, it also reduces the expression of
others.51–53 Furthermore, rodents that were bred based on
their high alcohol consumption exhibit not only upregulation
but also downregulation of gene expression in the brain
compare with their respective low drinking lines of mice and
rats.54–57 Another intriguing possibility is that inhibition of
DNMT1 and HDAC activity leads to increase in endogenous
factors that act to repress the level of alcohol drinking
behaviors. For example, the expression of the growth
factors, brain-derived neurotrophic factor (BDNF) and the
glial cell line-derived neurotrophic factor (GDNF), are regu-
lated by epigenetic modifications including DNA methylation
and histone acetylation,49,58,59 and both BDNF and GDNF are
endogenous inhibitors of alcohol intake that prevent the
escalation frommoderate to excessive consumption.60–69 It is
therefore plausible that HDAC and DNMT inhibition induces
increases in BDNF and GDNF expression, which may, in turn,
strengthen their action to inhibit excessive alcohol drinking.
Finally, it is also possible that HDAC and DNMT inhibitors
produce an increase in the expression of genes, which, in turn,
acts to reduce the expression of alcohol-responsive genes.
Further studies will be needed to identify specific genes and
pathways controlled by chromatin remodeling that allow the
robust reduction in excessive alcohol intake and alcohol
seeking.
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In contrast to our finding that the level of DNMT1 is
increased in the NAc of mice undergoing cycles of excessive
alcohol intake and withdrawal, Ponomarev et al.13 conducted
a post-mortem study and found that alcoholic subjects show a
DNA hypomethylation associated with a reduced expression
of DNMT1 in the amygdala and the superior frontal cortex, as
compared with control subjects. The difference between our
studies and Ponomarev et al. could be due to differences in
brain regions. In addition, our study does not differentiate
whether themolecular changes are due to the repeated cycles
of excessive alcohol intake and withdrawal which could also
be a potential reason for the differences between our results
and the human studies. Further studies are needed to
determine whether alcohol exposure leads to long-term
epigenetic changes after the cessation of alcohol exposure.
Another possibility for the differences between the present
study and Ponomarev et al.’s results is the fact that mice and
rats used in our study were not physically dependent on
alcohol. Our paradigms model ‘problem drinkers’, people who
engage in harmful excessive alcohol use but do not yet
meet criteria for alcohol use disorders.70 However, problem
drinkers are at great risk for developing severe alcohol use
disorders. Intervening in this vast population may be a way of
preventing the development and progression to full-fledged
alcohol use disorders. It is also very plausible that the
molecular changes in these two disease states are very
different. It is also possible that treatment with chromatin
remodeling inhibitors can prevent the escalation to physical
dependence.
In summary, it is plausible that chromatin structure
modifiers currently being used in the clinic or in clinical trials
represent a new therapeutic strategy to treat problem drinkers
who engage in harmful excessive alcohol use as well as
people with full-fledged alcohol use disorders. The lack of a
specific receptor target for alcohol in the brain positions a
potential treatment strategy that targets chromatin structure
as particularly promising.
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